A5040452356- Economic and Financial Impacts of Cancer
- Global Cancer Incidence and Screening
- Acute Lymphoblastic Leukemia research
- Colorectal Cancer Screening and Detection
- Health Systems, Economic Evaluations, Quality of Life
- Hematopoietic Stem Cell Transplantation
- Lymphoma Diagnosis and Treatment
- Multiple and Secondary Primary Cancers
- Childhood Cancer Survivors' Quality of Life
- Cervical Cancer and HPV Research
- CAR-T cell therapy research
Cancer represents a significant source of disease burden in the United States (US), both clinically and economically. Diagnosis treatment cancer at earlier stages may reduce this burden. To better understand potential impacts diagnosis, healthcare costs among patients with were assessed by type stage diagnosis.A retrospective analysis was conducted using Optum's de-identified Integrated Claims-Clinical data set Enriched Oncology, which includes from Medicare Advantage commercially insured...
Allogeneic hematopoietic cell transplantation (allo-HCT) has the potential for curative outcomes a variety of hematologic malignancies. Current allo-HCT studies often describe and costs in near term; however, research on lifetime economic burden post remains limited. To estimate average total direct medical an patient net monetary savings from alternative treatment associated with improved graft-versus-host disease (GVHD)-free relapse-free survival (GRFS). A disease-state model was...
BACKGROUND: Cancer diagnostic pathways are highly variable and not clearly established in the United States, which can lead to a diagnosis process that takes more time exposes patients invasive or unnecessary procedures, delays treatment, worsening patient outcomes, elevated health care resource utilization (HRU) system costs. OBJECTIVE: To investigate current trends diagnostic-related HRU preceding patient’s cancer across all types States. METHODS: A retrospective claims analysis was...
Aims Out-of-pocket (OOP) costs may constitute a substantial financial burden to patients diagnosed with cancer. Earlier stage diagnosis and treatment of cancers promote decreased morbidity mortality, subsequently also lowering costs. To better understand experienced by cancer, OOP post-diagnosis were estimated.
It is important to consider the total cost of care (TCOC) associated with a therapy and clinical benefit for relapsed or refractory (R/R) large B cell lymphoma (LBCL). We estimated 1-year TCOC per outcome patients R/R LBCL treated second-line lisocabtagene maraleucel (liso-cel) versus autologous stem transplantation (ASCT) using data from TRANSFORM study (ClinicalTrials.gov NCT03575351). A analysis Monte Carlo simulation approach was conducted. Cost inputs were generated retrospective...